What Theriva Biologics, Inc. does.

We are a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the Company’s acquisition of Theriva Biologics, S.L. (“VCN”, formerly named VCN Biosciences, S.L.), in March 2022, as described in more detail below (the “Acquisition”), we transitioned our strategic focus to oncology through the development of VCN’s new oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve access of co-administered cancer therapies to the tumor, and to promote a robust and sustained anti-tumor response by the patient’s immune system. Our lead product candidate, VCN - 01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus that is modified for tumor - selective replication and to express an enzyme, PH20 hyaluronidase. VCN - 01 has been evaluated in a Phase 2b clinical study for the treatment of pancreatic cancer (“VIRAGE”), and a Phase 1 clinical study for the treatment of retinoblastoma, as well as various other Phase 1 clinical studies for the treatment of other solid tumors including head and neck squamous cell carcinoma.

Revenue and profit, by fiscal year.

More on TOVX.

• Theriva Biologics, Inc. summary
• Theriva Biologics, Inc. financial statements
• Theriva Biologics, Inc. key metrics
• Theriva Biologics, Inc. health scores and style box
• Theriva Biologics, Inc. earnings
• Theriva Biologics, Inc. dividends
• Theriva Biologics, Inc. valuation
• Theriva Biologics, Inc. ownership and insiders
• Theriva Biologics, Inc. peers

Figures from Theriva Biologics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.